New hope for kids with tough leukemia: blinatumomab trial shows promise
NCT ID NCT06054113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called blinatumomab in 18 children (ages 1 month to 18 years) in China whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatment. The goal is to see if the drug can bring about complete remission and to check for side effects. Blinatumomab helps the immune system attack cancer cells, but ongoing monitoring and possible further treatment are needed, so it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Soochow University
Suzhou, Jiangsu, 215002, China
-
Childrens Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400015, China
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, 200127, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
-
Wuhan Childrens Hospital
Wuhan, Hubei, 430015, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.